Aclarion, Inc. has adopted a limited duration stockholder rights plan effective immediately through March 18, 2027, according to a company announcement. The plan, commonly known as a "poison pill," is designed to protect shareholders from hostile takeover attempts by ensuring any acquiring entity pays an appropriate control premium to all stockholders.
The Rights Plan applies equally to all current and future stockholders and was not adopted in response to any specific acquisition proposal. Instead, company officials stated the measure aims to provide the Board of Directors with sufficient time to make informed decisions in the best interests of Aclarion and its shareholders. The plan will help ensure all stockholders can realize the long-term value of their investment in the healthcare technology company.
Under the terms of the Rights Plan, Aclarion declared a dividend distribution of one preferred stock purchase right for each share of common stock and each Rights-Eligible Warrant outstanding as of March 30, 2026. These rights initially will not be exercisable and will trade alongside the company's common stock and warrants. Each right entitles the holder to purchase one one-thousandth of a share of Series D Junior Participating Preferred Stock at $14.00 per right, subject to adjustment.
The rights become exercisable if any entity, person, or group acquires beneficial ownership of 10% or more of Aclarion's common stock in a transaction not approved by the Board. Existing shareholders who already own 10% or more of common stock prior to the Rights Plan announcement are grandfathered but cannot increase their ownership without triggering the plan. If triggered, each right would entitle its holder to receive shares of common stock with market value equal to twice the exercise price, effectively diluting the acquirer's stake and making a hostile takeover prohibitively expensive.
This development is significant for investors and the broader healthcare technology sector as it demonstrates Aclarion's commitment to protecting shareholder value during a period of potential market volatility. The company, which focuses on chronic low back pain solutions through its Nociscan platform, is positioning itself to maintain strategic independence while pursuing growth initiatives. The Rights Plan contains no "dead-hand" provisions that would limit future boards from redeeming the rights, and the Board retains the option to exchange each right for one share of common stock or redeem them at $0.001 per right.
Additional information about the Rights Plan is available in the company's newsroom and will be detailed in a Form 8-K filing with the U.S. Securities and Exchange Commission. The adoption of such defensive measures often signals that a company's leadership believes the current market valuation may not reflect long-term potential, making this development particularly relevant for investors assessing healthcare technology opportunities in evolving markets.
